CSI Market
Sign In | Register

Definium Therapeutics Inc (DFTX) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access DFTX quarterly Cash Flow →
From Definium Therapeutics Inc through Dec 31 2020, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2020)
Operating Activities
Income-183.79
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation20.10
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants22.83
Non Cash Lease Expense-
Issuance Costs On Liability Classified Warrants-
Directors Deferred Share Units Expense-
Change In Fair Value On Directors Deferred Share Units1.46
Other Non Cash Adjustments-0.04
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable3.34
Increase (Decrease) in Accrued Liabilities5.96
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.15
Other Working Capital0.03
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.59
Discontinued operations0.00
Net Cash flow from Operating Activities-131.56
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities116.75
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments to Acquire Investments-268.36
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-151.61
Financing Activities
Short-term debt Net-22.00
Other borrowing transactions-0.45
Long-term debt - borrowings42.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock247.72
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payment Of Financing Warrants Issuance Costs-
Proceeds From Offering And Private Placement-
Proceeds From At The Market Offering Program Net Of Issuance Costs-
Proceeds From The March Offering And Private Placement-
Payment Of Deferred Financing Fees Related To At The Market-
Proceeds From Offerings And Private Placement-
Proceeds From Exercise Of Pre- Funded Warrants-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities267.27
Effect of exchange rate on cash flow-0.01
Discontinued operations0.00
Free Cash Flow-131.56
Total Cash Flow-15.90
4 historic quarters locked

Sign in to unlock the full Definium Therapeutics Inc cash flow history.

Sign In Create Free Account

About Definium Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 26, 2026
  • Source: dftx-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-076742

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License